Loading…
Getting the latest data.
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −2.3% | −5.2% | −5.0% | −12.7% | +4.3% | +10.3% | +61.8% | +12.9% | — | +21.9% |
| Peer average | −2.0% | −4.2% | −3.3% | −7.9% | +11.4% | +17.4% | +48.7% | +24.3% | +160.4% | — |
| S&P 500 · VOO | −2.0% | −5.5% | −7.4% | −6.3% | +5.8% | +9.7% | +65.8% | +65.5% | +290.0% | — |
$20 of every $1,000 in MMSC is Xometry,
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | XMTRXometry, () | Industrials | 2.01% | $201.48 | 8,628 | $992K |
| 2 | —US Dollar | — | 1.91% | $190.54 | 938K | $938K |
| 3 | FROGJFrog | Technology | 1.83% | $183.39 | 8,589 | $903K |
| 4 | ZETAZETA Global () | Technology | 1.66% | $165.87 | 24K | $816K |
| 5 | OLLIOllie's Bargain Outlet | Consumer Defensive | 1.56% | $155.82 | 8,127 | $767K |
| 6 | VRNSVaronis Systems | Technology | 1.39% | $138.61 | 14K | $682K |
| 7 | NTSKNetskope, () | Technology | 1.39% | $138.61 | 33K | $682K |
| 8 | TVTXTravere Therapeutics | Healthcare | 1.36% | $135.90 | 13K | $669K |
| 9 | SAILSailPoint | Technology | 1.32% | $131.73 | 32K | $648K |
| 10 | GHGuardant Health | Healthcare | 1.23% | $122.60 | 4,212 | $603K |
| 11 | SYRESpyre Therapeutics | Healthcare | 1.16% | $116.16 | 6,095 | $572K |
| 12 | PTGXProtagonist Therapeutics | Healthcare | 1.11% | $111.13 | 4,388 | $547K |
| 13 | RGENRepligen | Healthcare | 1.06% | $106.12 | 3,221 | $522K |
| 14 | LGNDLigand Pharmaceuticals () | Healthcare | 1.02% | $101.71 | 1,704 | $501K |
| 15 | GKOSGlaukos | Healthcare | 1.00% | $99.82 | 2,020 | $491K |
of the $574B in 112 Small cap ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | XMTR | Xometry, () | 2.01% |
| 2 | FROG | JFrog | 1.83% |
| 3 | ZETA | ZETA Global () | 1.66% |
| 4 | OLLI | Ollie's Bargain Outlet | 1.56% |
| 5 | VRNS | Varonis Systems | 1.39% |
| 6 | NTSK | Netskope, () | 1.39% |
| 7 | TVTX | Travere Therapeutics | 1.36% |
| 8 | SAIL | SailPoint | 1.32% |
| 9 | GH | Guardant Health | 1.23% |
| 10 | SYRE | Spyre Therapeutics | 1.16% |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 13, 2024 | Dec 31, 2024 | $0.0854 |